The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.
Agilent will offer Rubicon's amplification kits alongside one of its pre-screen kits, both of which are used in reproductive health testing.
Agilent plans to pay approximately €68 million in cash, and the deal is expected to be completed by mid-January.
Transcriptic will incorporate several of Agilent's genome engineering reagents into its cloud-based, remote access, automated biology research platform.
Agilent reported total revenues of $1.11 billion, up from $1.04 billion in the third quarter of 2015, and besting the average analyst estimate for revenues of $1.07 billion.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
The FDA has approved Merck's Keytruda as a first-line treatment for non-small cell lung cancer in patients with high PD-L1 expression.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.